Overview
The goal of this clinical trial is to learn if the use of cocktail of ropivacaine,sodium bicarbonate and dexamethasone for incision local infiltration analgesia in patients undergoing ambulatory laparoscopic cholecystectomy is safe and effective. The main questions it aims to answer are:
Does the cocktail lower the The incidence of moderate to severe pain during movement stages within six hours after surgery.
Researchers will compare the cocktail to ropivacaine for incision local infiltration analgesia to see if the cocktail works to moderate the postoperative pain of ambulatory laparoscopic cholecystectomy patients.
Participants will:
Receive the cocktail or ropivacaine for incision local infiltration analgesia at the end of the surgery.
Answer the questions about postsurgical pain at rest or during motion(using a Numeric Rating Scale (NRS) of 0 to 10. Pain measurements were performed at 2, 6, 12, 24 hours,3,7,30 days and 3 months postoperatively.
Eligibility
Inclusion Criteria:
- Patients undergoing daytime laparoscopic cholecystectomy in Sichuan Provincial
People's hospital ② Age: 18-70 years
- American society of Anesthesiologists physical status classification system
I-II ④ 18 kg/㎡≤ BMI ≤ 30 kg/㎡ ⑤ No communication barriers, able to understand
the research process and the use of pain scale.
- Signed informed consent
- American society of Anesthesiologists physical status classification system
I-II ④ 18 kg/㎡≤ BMI ≤ 30 kg/㎡ ⑤ No communication barriers, able to understand
the research process and the use of pain scale.
Exclusion Criteria:
- Drug allergy related to this study
- History of chronic pain, long-term use of analgesic drugs (equivalent to ≥ 10mg
oxycodone per day), alcohol abuse, gastrointestinal bleeding or perforation
after application of non steroidal anti-inflammatory drugs
- Patients with ischemic heart disease, peripheral arterial vascular or
cerebrovascular disease, or patients with pulmonary heart disease, active
peptic ulcer or gastrointestinal bleeding, or patients with inflammatory
bowel disease
- Patients taking monoamine oxidase inhibitors or within 2 weeks after discontinuation ⑤ Preoperative pain score (NRS ) was greater than or equal to 4 points ⑥ Participated in other clinical studies within three months
- Patients with ischemic heart disease, peripheral arterial vascular or
cerebrovascular disease, or patients with pulmonary heart disease, active
peptic ulcer or gastrointestinal bleeding, or patients with inflammatory
bowel disease
- History of chronic pain, long-term use of analgesic drugs (equivalent to ≥ 10mg
oxycodone per day), alcohol abuse, gastrointestinal bleeding or perforation
after application of non steroidal anti-inflammatory drugs